Antibiotics tied to poor NSCLC, melanoma TKI outcomes

Source: Medicine Matters, May 2022

medwireNews: Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors (TKIs) for advanced non-small-cell lung cancer (NSCLC) or melanoma, findings indicate.

“This work adds to an increasing body of evidence supporting a detrimental effect of [antibiotics] in patients receiving anticancer treatment,” write Natalie Cook (The Christie NHS Foundation Trust, Manchester, UK) and co-researchers in ESMO Open.

The analysis included data on 168 patients (89 with NSCLC, 79 with melanoma) who received first-line TKI therapy with dabrafenib, vemurafenib, gefitinib, afatinib, or erlotinib between January 2015 and April 2017 at The Christie NHS Foundation Trust. In all, 55 patients received antibiotics within 2 weeks prior to initiating TKIs and 6 weeks after.